MY201925A - Macrocyclic compounds and uses thereof - Google Patents

Macrocyclic compounds and uses thereof

Info

Publication number
MY201925A
MY201925A MYPI2019007871A MYPI2019007871A MY201925A MY 201925 A MY201925 A MY 201925A MY PI2019007871 A MYPI2019007871 A MY PI2019007871A MY PI2019007871 A MYPI2019007871 A MY PI2019007871A MY 201925 A MY201925 A MY 201925A
Authority
MY
Malaysia
Prior art keywords
compounds
macrocyclic compounds
csf1r
met
present disclosure
Prior art date
Application number
MYPI2019007871A
Other languages
English (en)
Inventor
Jingrong Jean Cui
Evan W Rogers
Jane Ung
Jeffrey Whitten
Dayong Zhai
Wei Deng
Xin Zhang
Zhongdong Huang
Jing Liu
Han Zhang
Original Assignee
Turning Point Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65039935&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY201925(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Turning Point Therapeutics Inc filed Critical Turning Point Therapeutics Inc
Publication of MY201925A publication Critical patent/MY201925A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MYPI2019007871A 2017-07-28 2018-07-26 Macrocyclic compounds and uses thereof MY201925A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762538193P 2017-07-28 2017-07-28
US201862700990P 2018-07-20 2018-07-20
PCT/US2018/043817 WO2019023417A1 (en) 2017-07-28 2018-07-26 MACROCYCLIC COMPOUNDS AND USES THEREOF

Publications (1)

Publication Number Publication Date
MY201925A true MY201925A (en) 2024-03-23

Family

ID=65039935

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2019007871A MY201925A (en) 2017-07-28 2018-07-26 Macrocyclic compounds and uses thereof

Country Status (29)

Country Link
US (4) US11286264B2 (https=)
EP (1) EP3658148B1 (https=)
JP (2) JP7224334B2 (https=)
KR (1) KR102645316B1 (https=)
CN (1) CN111182903A (https=)
AU (1) AU2018306328B2 (https=)
BR (1) BR112020001695A2 (https=)
CA (1) CA3069232A1 (https=)
CL (1) CL2020000169A1 (https=)
CO (1) CO2020000633A2 (https=)
DK (1) DK3658148T3 (https=)
ES (1) ES2986593T3 (https=)
FI (1) FI3658148T3 (https=)
HR (1) HRP20241197T1 (https=)
IL (1) IL271964B2 (https=)
LT (1) LT3658148T (https=)
MY (1) MY201925A (https=)
PE (1) PE20200700A1 (https=)
PH (1) PH12020500033A1 (https=)
PL (1) PL3658148T3 (https=)
PT (1) PT3658148T (https=)
RS (1) RS65884B1 (https=)
SA (1) SA520411108B1 (https=)
SG (1) SG11202000356VA (https=)
SI (1) SI3658148T1 (https=)
SM (1) SMT202400343T1 (https=)
TW (1) TWI818917B (https=)
UA (1) UA126158C2 (https=)
WO (1) WO2019023417A1 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3636649T3 (pl) 2014-01-24 2024-05-06 Turning Point Therapeutics, Inc. Diaryle makrocykliczne jako modulatory kinaz białkowych
ES2864839T3 (es) 2015-07-02 2021-10-14 Turning Point Therapeutics Inc Macrociclos de diarilo quirales como moduladores de proteína quinasas
FI3733187T3 (fi) 2015-07-21 2024-12-18 Turning Point Therapeutics Inc Kiraalinen diaryylimakrosykli ja sen käyttö syövän hoidossa
BR112019001607A2 (pt) 2016-07-28 2019-04-30 Tp Therapeutics, Inc. inibidores macrocíclicos de quinases
TWI808958B (zh) 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
US11286264B2 (en) 2017-07-28 2022-03-29 Turning Point Therapeutics, Inc. Macrocyclic compounds and uses thereof
CN109516999B (zh) * 2017-11-01 2021-08-17 郑州泰基鸿诺医药股份有限公司 用作蛋白质激酶调节剂的化合物及其应用
LT3728271T (lt) 2017-12-19 2022-12-12 Turning Point Therapeutics, Inc. Makrocikliniai junginiai, skirti ligų gydymui
WO2019206069A1 (zh) 2018-04-25 2019-10-31 北京普祺医药科技有限公司 一种二芳基巨环化合物、药物组合物以及其用途
AU2019364336B2 (en) 2018-10-22 2023-11-16 Alumis Inc. TYK2 inhibitors and uses thereof
CA3132632A1 (en) * 2019-03-11 2020-09-17 Esker Therapeutics, Inc. Tyk2 inhibitors and uses thereof
US12410191B2 (en) 2019-05-21 2025-09-09 Zhejiang Hisun Pharmaceutical Co., Ltd. Macrolide derivatives, preparation method and application thereof
WO2021063276A1 (zh) * 2019-09-30 2021-04-08 浙江海正药业股份有限公司 大环类衍生物及其制备方法和用途
IL295938A (en) * 2020-03-02 2022-10-01 Turning Point Therapeutics Inc Therapeutic uses of macrocyclic compounds
JP2023528907A (ja) * 2020-06-04 2023-07-06 シンノハブ ファーマシューティカル カンパニー，リミティド 大環状構造を有する化合物及びその使用
CN111620881B (zh) * 2020-07-08 2023-03-31 浙江合聚生物医药有限公司 拉罗替尼衍生物及其制备方法和应用
CN116635076A (zh) * 2020-12-17 2023-08-22 荣山医药股份有限公司 大环化合物及其用途
CN114685532A (zh) * 2020-12-31 2022-07-01 正大天晴药业集团股份有限公司 大环类化合物及其医药用途
US20240132517A1 (en) * 2021-02-10 2024-04-25 Goharmony Therapeutics (Shenzhen) Co., Ltd. Macrocyclic compound, pharmaceutical composition, and use thereof
UY39779A (es) * 2021-05-21 2023-01-31 Blossomhill Therapeutics Inc Compuestos macrocíclicos para tratar enfermedades
WO2023078267A1 (zh) * 2021-11-02 2023-05-11 赛诺哈勃药业（成都）有限公司 作为蛋白激酶调节剂的含氨基大环化合物
US12168640B2 (en) 2021-11-16 2024-12-17 ProDeg, LLC USP9X inhibitors
EP4433462A4 (en) * 2021-11-16 2025-07-16 Prodeg Llc USP9X INHIBITORS
TW202340177A (zh) 2021-12-30 2023-10-16 美商拜歐米富士恩股份有限公司 作為 flt3抑制劑之吡嗪化合物

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU679053B2 (en) 1993-03-25 1997-06-19 Pharmacia & Upjohn Company Indoletetralins having dopaminergic activity
NO308798B1 (no) 1993-12-07 2000-10-30 Lilly Co Eli Proteinkinase-C-hemmere, anvendelse av samme for fremstilling av farmasøytika samt farmasøytisk formulering omfattende samme
RS49779B (sr) * 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
EP1315732B1 (en) 2000-08-25 2006-06-07 Sloan-Kettering Institute For Cancer Research Radicicol and monocillin and their analogues and uses thereof
JP2004526676A (ja) 2000-12-08 2004-09-02 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド キナーゼ阻害剤として有用な大員複素環式化合物
US8815872B2 (en) 2008-09-08 2014-08-26 Merck Patent Gmbh Macrocyclics pyrimidines as aurora kinase inhibitors
PT2350075E (pt) 2008-09-22 2014-06-09 Array Biopharma Inc Compostos imidazo[1,2b]piridazina substituídos como inibidores da trk cinase
AR074052A1 (es) 2008-10-22 2010-12-22 Array Biopharma Inc Compuestos pirazolo{1,5-a}pirimidina sustituida como inhibidores de trk cinasa
CN102271515B (zh) 2008-10-31 2014-07-02 健泰科生物技术公司 吡唑并嘧啶jak抑制剂化合物和方法
WO2011045330A1 (en) 2009-10-13 2011-04-21 Tibotec Pharmaceuticals Macrocyclic integrase inhibitors
SA111320200B1 (ar) 2010-02-17 2014-02-16 ديبيوفارم اس ايه مركبات ثنائية الحلقة واستخداماتها كمثبطات c-src/jak مزدوجة
NZ604708A (en) * 2010-05-20 2015-05-29 Array Biopharma Inc Macrocyclic compounds as trk kinase inhibitors
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
EP2508607A1 (en) 2011-04-07 2012-10-10 Helmholtz-Zentrum für Infektionsforschung GmbH Medicament for liver regeneration and for treatment of liver failure
JP4868628B1 (ja) 2011-06-10 2012-02-01 株式会社メンテック 汚染防止剤組成物
WO2013001310A1 (en) 2011-06-30 2013-01-03 Centro Nacional De Investigaciones Oncológicas (Cnio) Macrocyclic compounds and their use as cdk8 inhibitors
EP2744331A4 (en) 2011-08-19 2015-01-21 Merck Sharp & Dohme METHOD AND INTERMEDIATE PRODUCTS FOR THE MANUFACTURE OF MACROLACTAMEN
CA2849999A1 (en) 2011-09-30 2013-04-04 Oncodesign S.A. Macrocyclic flt3 kinase inhibitors
HUE034118T2 (en) 2012-03-06 2018-01-29 Pfizer Macrocyclic derivatives for the treatment of proliferative diseases
RU2014140739A (ru) 2012-03-09 2016-04-27 Лексикон Фармасьютикалз, Инк. Соединения на основе имидазо[1, 2-b]пиридазина, композиции таких соединений и способы их применения
EP2834243B1 (en) 2012-03-09 2018-04-25 Lexicon Pharmaceuticals, Inc. PYRAZOLO[1,5-a]PYRIMIDINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE
GB201205669D0 (en) 2012-03-30 2012-05-16 Agency Science Tech & Res Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
WO2015073267A1 (en) 2013-11-15 2015-05-21 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
PL3636649T3 (pl) 2014-01-24 2024-05-06 Turning Point Therapeutics, Inc. Diaryle makrocykliczne jako modulatory kinaz białkowych
TWI736134B (zh) * 2014-09-11 2021-08-11 美商特普醫葯公司 作為蛋白質激酶之調節劑的二芳基巨環
ES2864839T3 (es) 2015-07-02 2021-10-14 Turning Point Therapeutics Inc Macrociclos de diarilo quirales como moduladores de proteína quinasas
JP6917974B2 (ja) 2015-07-06 2021-08-11 ターニング・ポイント・セラピューティクス・インコーポレイテッドＴｕｒｎｉｎｇ Ｐｏｉｎｔ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ジアリール大環状多形
FI3733187T3 (fi) * 2015-07-21 2024-12-18 Turning Point Therapeutics Inc Kiraalinen diaryylimakrosykli ja sen käyttö syövän hoidossa
RS63359B1 (sr) * 2015-11-06 2022-07-29 Incyte Corp Heterociklična jedinjenja kao inhibitori pi3k-gama
BR112019001607A2 (pt) * 2016-07-28 2019-04-30 Tp Therapeutics, Inc. inibidores macrocíclicos de quinases
AU2017348826B2 (en) * 2016-10-28 2021-12-02 Centaurus Biopharma Co., Ltd. Amino pyrazolopyrimidine compound used as neurotrophic factor tyrosine kinase receptor inhibitor
TWI808958B (zh) 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
US11286264B2 (en) 2017-07-28 2022-03-29 Turning Point Therapeutics, Inc. Macrocyclic compounds and uses thereof
CN109956957B (zh) 2017-12-22 2021-11-09 广州白云山医药集团股份有限公司白云山制药总厂 一种咪唑并[1,2-b]哒嗪大环类激酶抑制剂
WO2019201282A1 (zh) 2018-04-18 2019-10-24 成都先导药物开发股份有限公司 一种大环类激酶抑制剂

Also Published As

Publication number Publication date
US12606571B2 (en) 2026-04-21
EP3658148A4 (en) 2021-04-28
JP2020528907A (ja) 2020-10-01
TWI818917B (zh) 2023-10-21
PE20200700A1 (es) 2020-06-23
US11155563B2 (en) 2021-10-26
PT3658148T (pt) 2024-08-26
US20240391935A1 (en) 2024-11-28
CA3069232A1 (en) 2019-01-31
PL3658148T3 (pl) 2024-10-07
AU2018306328A1 (en) 2020-01-16
TW201920198A (zh) 2019-06-01
CO2020000633A2 (es) 2020-01-31
US11286264B2 (en) 2022-03-29
US11981684B2 (en) 2024-05-14
CN111182903A (zh) 2020-05-19
SA520411108B1 (ar) 2024-03-03
ES2986593T3 (es) 2024-11-12
KR20200034998A (ko) 2020-04-01
FI3658148T3 (fi) 2024-09-20
EP3658148B1 (en) 2024-07-10
IL271964B2 (en) 2024-12-01
JP7554300B2 (ja) 2024-09-19
KR102645316B1 (ko) 2024-03-07
AU2018306328B2 (en) 2023-03-09
WO2019023417A1 (en) 2019-01-31
EP3658148A1 (en) 2020-06-03
RS65884B1 (sr) 2024-09-30
US20200157119A1 (en) 2020-05-21
PH12020500033A1 (en) 2020-09-28
US20210214373A1 (en) 2021-07-15
SI3658148T1 (sl) 2024-10-30
JP2023065403A (ja) 2023-05-12
UA126158C2 (uk) 2022-08-25
SMT202400343T1 (it) 2024-11-15
US20220324879A1 (en) 2022-10-13
CL2020000169A1 (es) 2020-08-14
IL271964B1 (en) 2024-08-01
DK3658148T3 (da) 2024-10-07
SG11202000356VA (en) 2020-02-27
HRP20241197T1 (hr) 2024-11-22
IL271964A (en) 2020-02-27
JP7224334B2 (ja) 2023-02-17
BR112020001695A2 (pt) 2020-07-21
LT3658148T (lt) 2024-09-10

Similar Documents

Publication Publication Date Title
PH12020500033A1 (en) Macrocyclic compounds and uses thereof
PH12020550901A1 (en) Macrocyclic compounds for treating disease
MX2019001125A (es) Inhibidores de cinasa macrociclica.
PH12019501812A1 (en) Compositions and methods for the treatment of hemoglobinopathies
PH12018502535A1 (en) Substituted carbonucleoside derivatives useful as anticancer agents
AU2017228405A8 (en) Small molecule IRE1-alpha inhibitors
MX2018009773A (es) Heteroarilos inhibidores de peptidilarginina desiminasa 4 (pad4).
EP3848370A3 (en) Tyk2 inhibitors and uses thereof
MY192848A (en) Compositions and methods for the treatment of hemoglobinopathies
EA201891200A1 (ru) Композиции, содержащие бактериальные штаммы
MX2018005019A (es) Derivado benzofurano, su metodo de preparacion, y sus usos en medicinas.
MX2018006632A (es) Inhibidores biciclicos de peptidilarginina deiminasa 4 (pad4).
NZ722326A (en) Tricyclic compounds as anticancer agents
EP3735976A3 (en) Therapeutic use of mitochondria and combined mitochondrial agents
MY193524A (en) Diaryl macrocycles as modulators of protein kinases
EP4327809A3 (en) Tyk2 inhibitors and uses thereof
MX2016002075A (es) Inhibidores de indolamina 2,3-dioxigenasa (ido).
SG10201810879VA (en) Pharmaceutical compounds
PH12019501872A1 (en) Anti-tryptase antibodies, compositions thereof, and uses thereof
MX2022001310A (es) Compuesto de fenil-2-hidroxi-acetilamino-2-metil-fenilo.
MX2018006700A (es) Inhibidores aza-bencimidazol de peptidilarginina desiminasa (pad4).
MX2015014181A (es) 2-acetilnafto [2,3-b]furano -4,9-diona para uso en el tratamiento del cáncer.
MX378509B (es) Compuesto de pirimidina y su uso farmaceutico.
MX2016014559A (es) Compuestos para el tratamiento de cancer.
MX379622B (es) Compuestos espirociclicos